Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl (Molecular Cancer, (2010), 9, 1, (112), 10.1186/1476-4598-9-112);Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Lu, Zhongzheng ^a   Jin, Yanli ^a   Chen, Chun ^b   Li, Juan ^b   Cao, Qi ^a   Pan, Jingxuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE GAMMA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PRISTIMERIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER RESISTANCE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ADOLESCENT; ADULT; ANIMAL; CELL PROLIFERATION; CELL SEPARATION; CHILD; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NUDE MOUSE; POINT MUTATION;

CELASTRACEAE; MUS MUSCULUS;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SEPARATION; CHILD; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, NUDE; MIDDLE AGED; NF-KAPPA B; PIPERAZINES; POINT MUTATION; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 77952316523     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-021-01414-7     Document Type: Erratum

References (44)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453. 10.1038/nrc2147, 17522713.
2. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630. 10.1182/blood-2008-03-144790, 18827185.
3. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834-848. 10.1038/nrd2324, 17853901.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082. 10.1126/science.2408149, 2408149.
5. Baselga J, Arribas J. Treating cancer's kinase 'addiction'. Nat Med 2004, 10:786-787. 10.1038/nm0804-786, 15286778.
6. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006, 354:2594-2596. 10.1056/NEJMe068073, 16775240.
7. Druker BG, O'Brien SRL. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP):The 5-year update from the IRIS study [Abstract]. J Clin Oncol 2006, 24:18S.
8. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006, 145:913-923.
9. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer 2008, 122:2621-2627. 10.1002/ijc.23435, 18338755.
10. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, O'Cortes J, Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541. 10.1056/NEJMoa055229, 16775234.
11. Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V, Groffen J, Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007, 6:67. 10.1186/1476-4598-6-67, 2169263, 17958915.
12. Lounnas N, Frelin C, Gonthier N, Colosetti P, Sirvent A, Cassuto JP, Berthier F, Sirvent N, Rousselot P, Dreano M, Peyron JF, Imbert V. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int J Cancer 2009, 125:308-317. 10.1002/ijc.24294, 19378338.
13. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435. 10.1182/blood-2007-05-090621, 2234793, 17804695.
14. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000, 191:207-212. 10.1084/jem.191.2.207, 2195762, 10637266.
15. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307. 10.1182/blood.V98.8.2301, 11588023.
16. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol 2003, 31:504-511. 10.1016/S0301-472X(03)00069-9, 12829026.
17. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, Carturan S, Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, Martinelli G, Baccarani M, Saglio G. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006, 20:61-67. 10.1038/sj.leu.2403998, 16270044.
18. Dirsch VM, Kiemer AK, Wagner H, Vollmar AM. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol 1997, 336:211-217. 10.1016/S0014-2999(97)01245-4, 9384235.
19. Costa PM, Ferreira PM, Bolzani S, Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, de Moraes MO, Costa-Lotufo LV, Montenegro RC, Pessoa C. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro 2008, 22:854-863. 10.1016/j.tiv.2008.01.003, 18296021.
20. Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 2009, 113:4027-4037. 10.1182/blood-2008-09-179796, 19096011.
21. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 2005, 4:1277-1285. 10.1158/1535-7163.MCT-05-0027, 16093444.
22. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009, 15:1686-1697. 10.1158/1078-0432.CCR-08-2141, 19240172.
23. Lu Z, Jin Y, Qiu L, Lai Y, Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 2010, 290:182-191. 10.1016/j.canlet.2009.09.006, 19819619.
24. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010, 70:2516-2527. 10.1158/0008-5472.CAN-09-3950, 20215516.
25. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007, 109:315-322. 10.1182/blood-2006-04-013805, 16912224.
26. Blonska M, Shambharkar PB, Kobayashi M, Zhang D, Sakurai H, Su B, Lin X. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem 2005, 280:43056-43063. 10.1074/jbc.M507807200, 16260783.
27. Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther 2010, 9:211-223. 10.1158/1535-7163.MCT-09-0468, 20053766.
28. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005, 65:3671-3681. 10.1158/0008-5472.CAN-04-2744, 15867362.
29. Sakurai H, Miyoshi H, Toriumi W, Sugita T. Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation. J Biol Chem 1999, 274:10641-10648. 10.1074/jbc.274.15.10641, 10187861.
30. Anand P, Kunnumakkara AB, Harikumar KB, Ahn KS, Badmaev V, Aggarwal BB. Modification of cysteine residue in p65 subunit of nuclear factor-kappaB (NF-kappaB) by picroliv suppresses NF-kappaB-regulated gene products and potentiates apoptosis. Cancer Res 2008, 68:8861-8870. 10.1158/0008-5472.CAN-08-1902, 2673720, 18974130.
31. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
32. Shambharkar PB, Blonska M, Pappu BP, Li H, You Y, Sakurai H, Darnay BG, Hara H, Penninger J, Lin X. Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. EMBO J 2007, 26:1794-1805. 10.1038/sj.emboj.7601622, 1847656, 17363905.
33. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006, 66:10959-10966. 10.1158/0008-5472.CAN-06-1216, 17108134.
34. Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, Yuan X, Dou QP. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 2008, 103:234-244. 10.1002/jcb.21399, 17541980.
35. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112. 10.1038/sj.leu.2403145, 14574326.
36. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004, 104:509-518. 10.1182/blood-2003-12-4121, 15039284.
37. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998, 12:968-981. 10.1101/gad.12.7.968, 316671, 9531535.
38. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005, 105:2324-2331. 10.1182/blood-2004-08-3247, 15561889.
39. Griessinger E, Imbert V, Lagadec P, Gonthier N, Dubreuil P, Romanelli A, Dreano M, Peyron JF. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia 2007, 21:877-885.
40. Kiersnowska-Rogowska B, Izycka A, Jablonska E, Rogowski F, Parfienczyk A. Estimation of level of soluble form PECAM-1, ICAM-2 and TNF-alpha, IL-18 in serum patients with chronic myelogenic leukemia. Przegl Lek 2005, 62:772-774.
41. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995, 85:3636-3645.
42. Pan J. RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett 2010, 292:149-152. 10.1016/j.canlet.2009.11.018, 20045594.
43. Sawyers CL. Shifting paradigms, the seeds of oncogene addiction. Nat Med 2009, 15:1158-1161. 10.1038/nm1009-1158, 19812578.
44. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000, 11:355-360.